Dissolving Microstructure Array for Stable Vaccine Skin Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing microneedle arrays for transdermal drug delivery face challenges in providing stable formulation and effective administration of active agents without causing discomfort or chemical instability, particularly with the formation of subcutaneous nodules due to insoluble aluminum adjuvants.

Innovation Solution

A method of manufacturing microstructure arrays involving a liquid formulation of vaccine, insoluble particulate adjuvant, and hydrophilic polymer in an aqueous buffer, followed by dispensing, pressurization, and drying in a mold, resulting in a biocompatible and water-soluble matrix that dissolves upon penetration to deliver the vaccine and adjuvant without forming nodules.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If insoluble aluminum adjuvants are used in vaccine formulation, then immune response is enhanced, but subcutaneous nodules are formed causing discomfort

Engineering Contradiction:

Improveimmune response effectivenessVSAvoidsubcutaneous nodule formation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the physical state of the adjuvant from insoluble (aluminum salts) to soluble by using water-soluble polymers. This parameter change maintains the adjuvant's ability to enhance immune response while eliminating the harmful nodule formation associated with insoluble materials.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent converts the harmful effect of insoluble adjuvants (nodule formation) into a beneficial outcome by using water-soluble polymers that provide adjuvant activity without the harmful side effects. The soluble polymers dissolve in subcutaneous fluid, providing sustained release without nodule formation.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

2Ease of operation

If microneedle arrays are made disposable to eliminate sterilization needs, then ease of operation is improved, but manufacturing cost increases

Engineering Contradiction:

Improveelimination of sterilization and storage requirementsVSAvoidmanufacturing cost

Core Design Contradiction:

Ease of operationVSEase of manufacture

Solution Approach 1:

The patent employs disposable microneedle arrays that are inexpensive enough to be discarded after single use. This eliminates the need for sterilization and controlled storage, greatly simplifying operation and distribution, particularly in resource-limited settings.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The microneedle arrays use composite structures combining biodegradable polymers with vaccine formulations. This allows the arrays to be manufactured at low cost using simple processes while maintaining effectiveness, making disposable use economically viable.

Inventive Principle:

Principle #40Composite materials

3Ease of operation

If traditional liquid-based needle methods are used, then ease of administration is maintained, but chemical instability and discomfort increase

Engineering Contradiction:

Improveadministration convenienceVSAvoidformulation stability

Core Design Contradiction:

Ease of operationVSStability of the object's composition

Solution Approach 1:

The patent transitions the vaccine formulation from liquid state to solid state by incorporating it into microneedle arrays. This phase transition stabilizes the formulation, eliminating chemical degradation issues associated with liquid storage while maintaining ease of administration through painless microneedle application.

Inventive Principle:

Principle #36Phase transitions

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method ensures stable delivery of therapeutically effective amounts of active agents with reduced discomfort and nodule formation, enhancing immune response while maintaining formulation stability during manufacturing, storage, and administration.

Implementation Method 1

a biocompatible and water-soluble matrix that dissolves upon penetration to deliver the vaccine and adjuvant

Methodology Applied

Scientific EffectAbsorption: Absorption (physical)

Implementation Method 2

drying the formulation present in the mold

Methodology Applied

Scientific EffectEvaporation: Evaporation

Data Source

PatentUS20260083948A1Microstructure array for delivery of active agents

Publication Date: 2026.03.26 PANTHER LIFE SCIENCES CORP

AI summary

Provided herein is a microstructure array comprising a plurality of dissolving microstructures such as microprojections attached to a base. The plurality of microstructures comprise an active agent in a biocompatible and water-soluble matrix, where the water-soluble matrix preferably comprises a polysaccharide polymer and a sugar alcohol, and the base typically comprises a non-water soluble matrix. The plurality of microstructures, upon penetration of the subject's skin, undergo dissolution to deliver the active agent. Also provided are related microstructure formulations, in dried and liquid form, methods for preparing the above-described microstructure arrays, and methods for administering an active agent by application of a microstructure array as provided herein to a subject's skin, among other features.